Evidence map›Paper›PMID 40197203›Full record

ReviewCurrent drug delivery2026

Optimizing Transdermal Drug Delivery with Novasome Nanocarriers: A Quality by Design (QbD) Framework.

Prabhjot Kaur, Priyanka Kriplani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Prabhjot KaurDepartment of Pharmaceutics, Guru Gobind Singh College of Pharmacy, Yamuna Nagar 135001, Haryana, India.
Priyanka KriplaniDepartment of Pharmaceutics, Guru Gobind Singh College of Pharmacy, Yamuna Nagar 135001, Haryana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A revolutionary encapsulation-based drug delivery technique called novasome technology outperforms conventional liposome systems in terms of effectiveness and efficiency. It is comprised of free fatty acid, cholesterol, and surfactant, which combine to yield better vesicle properties for medication administration. Numerous research endeavors have examined the ideal blend of surfactant types, free fatty acids, and their proportions, along with the formulation elements that might substantially impact the vesicle properties. It has been shown that novasome technology may be used to deliver various drugs, such as vaccines, niflumic acid, zolmitriptan, and terconazole. To develop the most effective novasomal formulations with significant drug loading and nano-metric form, it is important to find the appropriate ratio between core components along with critical manufacturing process determinants. Understanding the interplay between these factors requires applying Quality by Design (QBD) in combination with Design of Experiments (DoE). These may be applied for both scale-up and lab-scale applications. This manuscript includes a detailed view of novasomes and the involvement of QBD.

Indexed as

Drug CarriersDrug Delivery SystemsNanoparticlesAdministration, CutaneousAnimalsHumansLiposomesSurface-Active AgentsDrug CarriersLiposomesSurface-Active Agentsconventional liposomesfree fatty acidNovasomesnovel nanocarriersquality by designsurfactanttransdermal deliveryvesicular system

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.